AFIB Acutus Medical

Acutus Medical Obtains MDR CE Mark of the AcQMap 3D Imaging and Mapping Catheter

Acutus Medical Obtains MDR CE Mark of the AcQMap 3D Imaging and Mapping Catheter

The flagship 3D mapping catheter from Acutus Medical has been certified under the new European Medical Device Regulations

CARLSBAD, Calif., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or “the Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced receipt of a CE Mark issued under the European Union (EU) Medical Device Regulations (MDR) for its AcQMap 3D Imaging and Mapping Catheter, the world’s only integrated high-resolution ultrasound imaging and non-contact mapping catheter.

The EU MDR was established to create a more robust legislative framework to better protect public health and patient safety. Acutus will file for EU MDR approval for the remaining products in the Company’s portfolio to ensure compliance by the May of 2024 deadline. This will allow physicians to have long-term access to the Company’s full portfolio of differentiated mapping, ablation, and EP accessory products.

“Obtaining our MDR CE Mark for AcQMap well before the transition date ensures that European patients and physicians will have continued access to our unique mapping technology offering individualized diagnosis and a personalized treatment plan for even the most complex arrhythmias,” said Shibaji Shome, Vice President, Marketing at Acutus. “The MDR, with a significant focus on quality and safety, is well aligned with our commitment to improve patient care through innovative and high-quality medical devices. Importantly, this approval positions us well for further expansion and growth within the European markets.”

In addition, the Company received MDR certification of its quality management system.

To learn more about Acutus Medical’s complete portfolio of diagnostic, access and therapy products, please visit .

About Acutus Medical

Acutus Medical is an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated. Acutus is committed to advancing the field of electrophysiology with a unique array of products and technologies which will enable more physicians to treat more patients more efficiently and effectively. Through internal product development, acquisitions and global partnerships, Acutus has established a global sales presence delivering a broad portfolio of highly differentiated electrophysiology products that provide its customers with a complete solution for catheter-based treatment of cardiac arrhythmias. Founded in 2011, Acutus is based in Carlsbad, California.

Follow Acutus Medical on: , , and .

Investor Contact

Caroline Corner

415-202-5678



EN
06/12/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Acutus Medical

 PRESS RELEASE

Acutus Medical Reports Full Year 2024 Financial Results

Acutus Medical Reports Full Year 2024 Financial Results CARLSBAD, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (OTC: AFIB) today reported results for the full year of 2024. Recent Highlights: 2024 Revenue from Continuing Operations of $20.2 million grew 181% year-over-year, from $7.2 million last year.Operating loss for continuing operations was $0.1 million, compared to 11.7 million last year.Recorded $10.8 million in gain on sale of business, an increase of 19% compared to last year.Cash, cash equivalents, marketable securities and restri...

 PRESS RELEASE

Acutus Medical Announces Operational Downsizing

Acutus Medical Announces Operational Downsizing CARLSBAD, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), today announced a realignment of resources and operational downsizing. Dr. Shaden Marzouk, Chairperson of the Board of Directors of Acutus, commented, “Following an extensive strategic review by the Company’s Board of Directors, we are taking the hard but necessary steps to reduce the size of our organization while complying with our remaining obligations to Medtronic for the production of left-heart access products.” Takeo ...

 PRESS RELEASE

Acutus Medical Reports Third Quarter and Year-To-Date 2024 Financial R...

Acutus Medical Reports Third Quarter and Year-To-Date 2024 Financial Results CARLSBAD, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (OTC: AFIB) today reported results for the third quarter and year-to-date of 2024. Recent Highlights: Third quarter revenue from Continuing Operations of $5.3 million grew 156% year-over-year, from $2.1 million in the same quarter last year.Operating income for continuing operations was $0.1 million, an improvement of 119% compared to the same period last year.Recorded $2.4 million in gain on sale of bus...

 PRESS RELEASE

Acutus Medical Reports Second Quarter and Year-To-Date 2024 Financial ...

Acutus Medical Reports Second Quarter and Year-To-Date 2024 Financial Results CARLSBAD, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (OTC: AFIB) today reported results for the second quarter and year-to-date of 2024. Recent Highlights: Second quarter revenue from Continuing Operations of $4.1 million grew 172% year-over-year, from $1.5 million in the same quarter last year.Operating expenses for continuing operations were $2.2 million, a reduction of 47% compared to the same period last year.Recorded $2.9 million in gain on sale of business,...

 PRESS RELEASE

Acutus Medical Reports First Quarter 2024 Financial Results

Acutus Medical Reports First Quarter 2024 Financial Results CARLSBAD, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (OTC: AFIB) today reported results for the first quarter of 2024. Recent Highlights: First quarter revenue from Continuing Operations of $3.6 million grew 192% year-over-year, from $1.2 million in the same quarter last year..Operating expenses for continuing operations were $3.3 million, a reduction of 38% compared to the same period last year.Recorded $2.8 million in gain on sale of business, an increase of 131% compared to ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch